SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.
In the U.S., orthobiologics revenue is expected to grow +12% vs. 4Q16, to reach ~$16.9MM, while U.S. spinal hardware revenue should remain flat year-over-year at $14.6MM.
The company announced full-year 2018 guidance in the range of $135.0MM to $139.0MM, for potentially 5% growth vs. 2017.
SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.
In the U.S., orthobiologics revenue is expected to grow +12% vs. 4Q16, to reach ~$16.9MM, while U.S. spinal hardware revenue should remain flat...
SeaSpine reported preliminary 4Q17 revenue in the range of US $34.2MM to $34.4MM, +5.8% vs. 4Q16, and a 2017 revenue range of $132.0MM to $132.2MM, +2.6% vs. 2016.
In the U.S., orthobiologics revenue is expected to grow +12% vs. 4Q16, to reach ~$16.9MM, while U.S. spinal hardware revenue should remain flat year-over-year at $14.6MM.
The company announced full-year 2018 guidance in the range of $135.0MM to $139.0MM, for potentially 5% growth vs. 2017.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
